Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports

CONCLUSIONS: Our study demonstrates that remdesivir, a novel drug applied to the treatment of COVID-19, does not have a significant association with adverse neurologic or psychiatric reactions in the real-world setting.PMID:34919240 | DOI:10.26355/eurrev_202112_27435

Source: Pharmacological Reviews - December 17, 2021 Category: Drugs & Pharmacology Authors: S Lee J W Yang S Y Jung M S Kim D K Yon S W Lee H-C Kang E Dragioti K Tizaoui L Jacob A Koyanagi J-E Salem K Kostev A Lascu J I Shin J H Kim L Smith Source Type: research